We provide you with 20 years of free, institutional-grade data for IMCR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IMCR. Explore the full financial landscape of IMCR stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Berman David M | Sale | -36,509 | $67.61 | $2,468,373 | 2024-03-01 |
| Berman David M | Derivatives Exercise | 36,509 | 2024-03-01 | ||
| Berman David M | Sale | -83,491 | $70.6 | $5,894,465 | 2024-02-28 |
| Berman David M | Derivatives Exercise | 83,491 | 2024-02-28 | ||
| St Leger Tina Amber | Sale | -4,375 | $69.85 | $305,594 | 2024-01-05 |
| St Leger Tina Amber | Derivatives Exercise | 4,375 | 2024-01-05 | ||
| Ratcliffe Peter John | Initial | 2024-01-02 | |||
| Bell John Irving | Initial | 2024-01-02 | |||
| Di Donato Brian | Initial | 2024-01-02 |
The information provided in this report about IMCR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Immunocore Holdings plc(NASDAQ:IMCR) 
Immunocore Holdings plc, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase 3 clinical trial in patients with previously untr...
Share this website to your friends